Suprane Liquid
Product Images NDC 0404-9961

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 19 technical images submitted to the FDA as part of the official labeling for Suprane (NDC 0404-9961). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Henry Schein, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1.jpg (Figure1)

FDA Label Image

Figure2.jpg (Figure2)

Figure2.jpg (Figure2)
This is a figure from a medical study that shows the washin of desflurane in eight healthy male volunteers who received nitrous oxide and different levels of desflurane, isoflurane, and halothane through inhalation. The figure plot shows the mean and standard deviation of the end-tidal anesthetic concentration over time in minutes.*
FDA Label Image

Figure3.jpg (Figure3)

Figure3.jpg (Figure3)
The text describes a figure depicting the washout of a gas anesthetic in 8 male volunteers. The figure shows mean and standard deviation values at different concentrations of the anesthetic over time. The anesthetics used were Halothane, Isoflurane, and Desflurang. The X-axis shows time in minutes, and the Y-axis shows the concentration of the anesthetic in the breath of the patient.*
FDA Label Image

Formula1.jpg (Formula1)

FDA Label Image

Image1.jpg (Image1)

Image1.jpg (Image1)
This is a table reporting the frequency and types of adverse reactions reported in patients from clinical trials and postmarketing experience. The reactions are grouped by system/organs affected such as Cardiovascular, Digestive, Nervous System, Respiratory, etc. For each group, the specific reactions that occurred in at least 3 patients regardless of severity are listed. The reactions that are rare and not seen in clinical trials are italicized.*
FDA Label Image

Image2.jpg (Image2)

Image2.jpg (Image2)
The provided text gives information about various physical constants and partition coefficients for a substance, including molecular weight, specific gravity, vapor pressure, blood/gas partition coefficient, olive oil/gas partition coefficient and various mean component/gas partition coefficients. The substance has a boiling point of 757 mm Hg at 22.6°C and partition coefficients at 37°C for blood/gas, olive oil/gas and brain/gas are 0.424, 187 and 0.54, respectively. Mean component/gas partition coefficients are also given for substances such as polypropylene, polyethylene, latex rubber and polyvinyl chloride.*
FDA Label Image

Image3.jpg (Image3)

Image3.jpg (Image3)
This is a table of data related to the emergence and recovery of 178 female patients aged between 20 and 47 who underwent outpatient laparoscopy under anesthesia. The table shows the different anesthesia types used, including the types of drugs used in the induction and maintenance stages, and the number of patients for each type. The table also presents data on the median age of patients, the duration of anesthesia, the time it took for patients to open their eyes, state their name, stand, walk, and become fit for discharge. The Dunnett's procedure was used to compare all treatments to the propofol-propofol/N,0 group, and the results showed statistically significant differences (p < 0.05). However, after one hour of anesthesia, the comparisons between groups showed no differences, and there was considerable variability within groups.*
FDA Label Image

Image4.jpg (Image4)

Image4.jpg (Image4)
This article presents a study on emergence and recovery times in outpatient surgery. The study included 46 males and 42 females, aged 19-70. Times in minutes were recorded for different stages of anesthesia administration, and the results were compared using statistical analysis. The study found statistically significant differences between treatments when compared to the thiopental-isoflurane/N;0 group. However, after one hour, no differences were found between groups.*
FDA Label Image

Image5.jpg (Image5)

Image5.jpg (Image5)
This document presents the results of recovery tests performed on 16 males and 22 females aged 20-65, measuring the percent of the preoperative baseline values after 60 and 90 minutes following anesthesia. The tests evaluated confusion, fatigue, drowsiness, clumsiness, comfort, DSST+ score, and Trieger Tests++. The values of the tests, recorded as Mean + SD, were compared to the baseline values using a two-sample t-test. Additionally, the document includes a visual analog scale with a range of values from 0-100, where 100 represents the baseline. The DSST (Digit Symbol Substitution Test) and Trieger Test (Dot Connecting Test) are indicated as well.*
FDA Label Image

Image6.jpg (Image6)

Image6.jpg (Image6)
This is a report on the hemodynamic effects of desflurane during controlled ventilation in 12 male volunteers aged 16-26. The report presents data on heart rate, mean arterial pressure, and cardiac index at different levels of total MAC and end-tidal concentrations of oxygen and desflurane. The results show statistically significant differences compared to awake values using Newman-Keul's method of multiple comparison.*
FDA Label Image

Image7.jpg (Image7)

Image7.jpg (Image7)
This text presents data about cardiovascular patients separated by agent and type of surgery. It includes the number of male and female patients, their ages, and the number of centers where the surgeries were performed. The types of surgeries include CABG, abdominal aorta, peripheral Vass, and carotid art. The agents used during the surgeries were isoflurane, desflurane, and sufentanil or fentanyl. However, the data is incomplete and lacks an explanation of the symbols used in the text.*
FDA Label Image

Image8.jpg (Image8)

Image8.jpg (Image8)
This document provides an overview of the respiratory events experienced by 300 non-intubated pediatric patients during maintenance that involved the use of a face mask or LMA. The events are broken down by age group (26y, 71yr, 12-16yr) and include information on the percentage of patients who experienced each event. The events fall under categories such as airway obstruction, coughing, and non-specific desaturation.*
FDA Label Image

Image9.jpg (Image9)

Image9.jpg (Image9)
This is a list of products and their corresponding NDG Container Unit numbers. It includes an amber-colored container unit, six glass container units, and an aluminum bottle. Each product also has a unique product number associated with it.*
FDA Label Image

Label1.jpg (Label1)

Label1.jpg (Label1)
SUPRANE is a non-flammable and non-explosive anaesthetic which comes in a liquid form that can be inhaled. It is also known as Desflurane, USP. The product label advises replacing the cap after every use and storing it away from children at a temperature between 15-30 degrees Celsius. The product is (presumably) intended for human use as the label mentions prescribing information. However, there is insufficient information to evaluate the effectiveness or safety of SUPRANE for any particular use.*
FDA Label Image

Table1.jpg (Table1)

Table1.jpg (Table1)
This is a table presenting the effects of age on minimum alveolar concentration of Desflurane. The table shows mean and standard deviation in percentage atmospheres for different ages ranging from 2 weeks to 70 years. The table also mentions the number of crossover pairs using an up-and-down method of quantal response.*
FDA Label Image

Table2.jpg (Table2)

Table2.jpg (Table2)
The provided text describes the frequency of events occurring in clinical trial patients who used an inhalation agent as a mask during induction and maintenance or recovery. The text includes data related to adult and intubated pediatric patients along with the frequency of symptoms such as coughing, apnea, increased secretions, headache, cardiovascular issues, digestive issues, and respiratory issues such as laryngospasm, pharyngitis, breath-holding, etc. The report also mentions an increased incidence of events between 3% - 10%.*
FDA Label Image

Table3.jpg (Table3)

FDA Label Image

Table4.jpg (Table4)

Table4.jpg (Table4)
The table shows the dosage of different muscle relaxants which causes a 95% depression in neuromuscular blockade. The data includes mean EDg values (ug/kg) for Desflurane Concentration, Pancuronium, Atracurium, Suceinylcholine, and Vecuronium at different doses.*
FDA Label Image

Table5.jpg (Table5)

Table5.jpg (Table5)
This is a study that compares the recovery profiles of outpatients who were given either Desflurane 3% in N,0 60% or Isoflurane 0.6% in N,O 60%. The study included 16 males and 22 females aged 20-65. The data show the mean and standard deviation for various recovery times, such as the time it took for patients to follow commands, sit up, and be fit for discharge. It was noted that the difference between the two groups was statistically significant with a p-value less than 0.05.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.